Trial Profile
Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Carboplatin
- Indications Breast cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- 06 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
- 06 Jun 2019 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2020.
- 30 Jun 2016 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.